These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 37867187)
1. Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article. Youssry I; Ayad N Ann Hematol; 2024 Aug; 103(8):2613-2619. PubMed ID: 37867187 [TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 gene editing for curing sickle cell disease. Park SH; Bao G Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878 [TBL] [Abstract][Full Text] [Related]
3. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. Wen J; Tao W; Hao S; Zu Y J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635 [TBL] [Abstract][Full Text] [Related]
4. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717 [TBL] [Abstract][Full Text] [Related]
5. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34 Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133 [TBL] [Abstract][Full Text] [Related]
6. Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Abdallah K; Huys I; Claes KJ; Simoens S Clin Drug Investig; 2024 Aug; 44(8):611-627. PubMed ID: 39134876 [TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-based gene-editing technology for sickle cell disease. Ma L; Yang S; Peng Q; Zhang J; Zhang J Gene; 2023 Jul; 874():147480. PubMed ID: 37182559 [TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges. Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679 [TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943 [TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 system and its applications in human hematopoietic cells. Hu X Blood Cells Mol Dis; 2016 Nov; 62():6-12. PubMed ID: 27736664 [TBL] [Abstract][Full Text] [Related]
15. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease. Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541 [TBL] [Abstract][Full Text] [Related]
16. Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. Bauer DE; Brendel C; Fitzhugh CD Blood Cells Mol Dis; 2017 Sep; 67():155-168. PubMed ID: 28893518 [TBL] [Abstract][Full Text] [Related]
17. Effective therapies for sickle cell disease: are we there yet? Crossley M; Christakopoulos GE; Weiss MJ Trends Genet; 2022 Dec; 38(12):1284-1298. PubMed ID: 35934593 [TBL] [Abstract][Full Text] [Related]
18. Gene Therapy as the New Frontier for Sickle Cell Disease. Garg H; Tatiossian KJ; Peppel K; Kato GJ; Herzog E Curr Med Chem; 2022; 29(3):453-466. PubMed ID: 34047257 [TBL] [Abstract][Full Text] [Related]
19. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation for engraftment of CD34 Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]